Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials.
about
Blood pressure lowering effect of diuretics as second line therapy for primary hypertension in crossover trialsGenetic variants in novel pathways influence blood pressure and cardiovascular disease riskUse of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesBeta-Blockers in the Management of Hypertension and/or Chronic Kidney DiseaseAn evolving story of angiotensin-II-forming pathways in rodents and humansHypertension and chronic kidney disease: controversies in pathogenesis and treatmentIs blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) andVascular Disease in Young Indians (20-40 years): Role of HypertensionCardiac remodelling and RAS inhibitionA Targeted Metabolomics MRM-MS Study on Identifying Potential Hypertension Biomarkers in Human Plasma and Evaluating Acupuncture EffectsNovel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease.Healthy Ageing Through Internet Counselling in the Elderly: the HATICE randomised controlled trial for the prevention of cardiovascular disease and cognitive impairment.Peripheral and central arterial pressure and its relationship to vascular target organ damage in carotid artery, retina and arterial stiffness. Development and validation of a tool. The Vaso risk studyAngiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate.Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects.Standard and Novel Treatment Options for Metabolic Syndrome and Diabetes MellitusAmlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapyThe 2017 Focused Update of the Guidelines of the Taiwan Society of Cardiology (TSOC) and the Taiwan Hypertension Society (THS) for the Management of HypertensionSex, BMI and age differences in metabolic syndrome: the Dutch Lifelines Cohort StudyApparent and true resistant hypertension: definition, prevalence and outcomesAn international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality.2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by represImpact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population.Management of essential hypertension.Hypertensive nephropathy: prevention and treatment recommendations.Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial.Stopping the cardiovascular disease continuum: Focus on prevention.Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy.Cost-effectiveness of antihypertensive treatment in patients 80 years of age or older in Switzerland: an analysis of the HYVET study from a Swiss perspectiveThe ACTION study: nifedipine in patients with symptomatic stable angina and hypertension.The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe.Olmesartan medoxomil for the treatment of hypertension in children and adolescentsRacial differences in response to antihypertensive therapy: does one size fits all?Hemodynamic and hormonal patterns of untreated essential hypertension in men and women.Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trialUnanswered clinical questions in the management of cardiometabolic risk in the elderly: a statement of the Spanish Society of Internal Medicine.Calcium channel blocker enhances beneficial effects of an angiotensin II AT1 receptor blocker against cerebrovascular-renal injury in type 2 diabetic miceOlmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies.
P2860
Q24241304-39383538-3469-4D9E-AD96-2716D6C58ACAQ24630394-28E91F69-037B-4C72-8157-7B53CE5597F6Q24658205-ECEFDBDC-5DE6-40BB-8815-9302FAA5CDA3Q26825409-7EA271D2-759F-4E32-AF98-C8419B04DAE0Q26830036-C8D3BEDA-9FDB-432A-A679-F4C5B88DBAA3Q26851271-3C8F1653-EB95-498D-9E13-3BDD9F0593B7Q27025943-018F9B9E-4F44-4112-BE08-DCECEE887D71Q28074249-566ABF66-5A36-40A3-8A5E-BE25ABBFAAE1Q28076749-082428D0-D1B3-4155-AC2F-CB463E053AE3Q28834202-CAF5A2F5-4DB7-4394-A5E6-520D786CDF8FQ30235583-9DEC82E5-2E23-4C18-8C9A-AD5F1C85C2DEQ30489448-1B10955F-A0EA-4BD5-A1AA-6C16DB99F53BQ31007504-EF47B12F-E703-48B1-832F-0B6EA89851E7Q33554921-5EF0C77F-BDEB-4E50-899D-AC11CE524EC5Q33561456-AE5A87C1-5552-4661-BAF4-B346E1BBE995Q33618721-C3BC3B20-31A8-4ACA-BFAB-F2676A53E606Q33639606-7835E4ED-5250-4426-A8A8-28A3CF3E303BQ33729817-1A5A63EF-8078-4847-BF8B-5824EFEC3E41Q33759059-DD25CDEC-EF16-4F43-BBF1-883BE8E904F5Q33875656-84967455-AC68-49D5-9EBF-1F5394D19EDAQ33925329-2E89E6A4-9CA7-4107-80CA-1DABCF0C814BQ33993233-EC16BBAC-4C01-480A-AB36-F7F96B35E147Q33995658-29AF8755-9CEA-4BB8-B027-CD68C415AC6AQ34046881-BDE3BFE2-80A7-40DE-84F7-C3F6F58BA557Q34060319-CBDAB45A-83DE-4DE5-8EBB-137883B17928Q34097871-25A16702-9D08-476C-94B0-CD7356F40AA7Q34131899-9CD8FD63-991D-49BD-B843-12874D1C0643Q34196851-0C9427FE-BEB5-4F8D-ABF6-4FABD794B59DQ34390558-5E0EF4D3-415C-445F-8C3D-21EA0B80598AQ34432806-28A3F4BC-E8D6-428C-8DBC-BD140DD17EADQ34444643-5A733A0C-D502-4382-928F-4F1FE673CF48Q34597185-9C463005-3F24-4F11-A631-3DA6CEA0CBFEQ34746089-0EE7ECF7-EB9F-47DF-952D-E9B4B6B28880Q34772915-1EF2096A-1CF3-4BB7-9D23-449B07CFB538Q34786568-8C072F2F-C18C-4CAA-BD4E-2335694AF25EQ34794633-A8E99A88-9939-46BD-851E-01045F10EAA3Q34876994-B160FFD5-75AA-4836-AEA6-451955D346E8Q34901444-B00C59EC-8632-48F4-876E-272FE9DD4AE3Q35067693-F24E0DCD-8341-4330-832E-394F3489F582Q35085669-71E44991-5206-4338-B146-BA60BA036045
P2860
Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Effects of different regimens ...... analysis of randomised trials.
@ast
Effects of different regimens ...... analysis of randomised trials.
@en
Effects of different regimens ...... analysis of randomised trials.
@nl
type
label
Effects of different regimens ...... analysis of randomised trials.
@ast
Effects of different regimens ...... analysis of randomised trials.
@en
Effects of different regimens ...... analysis of randomised trials.
@nl
prefLabel
Effects of different regimens ...... analysis of randomised trials.
@ast
Effects of different regimens ...... analysis of randomised trials.
@en
Effects of different regimens ...... analysis of randomised trials.
@nl
P2093
P2860
P1433
P1476
Effects of different regimens ...... analysis of randomised trials.
@en
P2093
Blood Pressure Lowering Treatment Trialists' Collaboration
F Turnbull
J Chalmers
M Woodward
P2860
P304
P356
10.1136/BMJ.39548.738368.BE
P407
P577
2008-05-14T00:00:00Z